Haloperidol Pharmacokinetics after Oral and Intravenous administration in Elderly
Withdrawn
- Conditions
- acute confusional statedelirium10012221
- Registration Number
- NL-OMON43207
- Lead Sponsor
- Kennemer Gasthuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
hip fracture surgery
65 years or over
DRAS score 5 or over
informed consent
Exclusion Criteria
haloperidol allergy
QTc prolongation
Parkinsons's disease
Lewy body dementia
use of anticoagulents
liver failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Nonlinear mixed effects model describing the population pharmacokinetics of<br /><br>haloperidol in the central and peripheral compartment after oral and<br /><br>intravenous injection.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Occurrence of adverse events and occurrence of postoperative delirium</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie haloperidol's dopamine D2 receptor antagonism in elderly delirium patients?
How does haloperidol's oral vs intravenous pharmacokinetics compare to standard-of-care antipsychotics in geriatric delirium management?
Which biomarkers correlate with haloperidol plasma concentration variability in acute confusional state treatment?
What adverse event profiles are observed with haloperidol in elderly populations compared to atypical antipsychotics?
How do CYP2D6 polymorphisms influence haloperidol metabolism and delirium treatment outcomes in older adults?